| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2019/031 | ||
|---|---|---|---|
| Date of filing | 17/05/2019 | ||
| Notification of Application Published | 26/06/2019 | ||
| Status | Granted | ||
| Notification of Grant Published | 13/05/2020 | ||
| Date of Expiry of SPC | 25/11/2033 | ||
| Applicant |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome Chuo-ku Osaka-shi Osaka JAPAN |
||
| Patent Number | 2300013 | ||
| Title of Invention | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ||
| Date of Expiry of Patent | 20/05/2029 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Brigatinib, or a pharmaceutically acceptable salt thereof. | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/18/1264 | ||
| Authorisation Date | 22/11/2018 | ||
| Identity of Product Authorised | ALUNBRIG - Brigatinib | ||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||
| Renewal Fees | |||
| 22/04/2020 | Supplementary Protection Certificate Number 2019/031, having an expiry date of 25/11/2033 granted on 22/04/2020. | ||
| 15/07/2021 | Change of Proprietorship from ARIAD PHARMACEUTICALS, INC., 26 Landsdowne Street, Cambridge, MA 02139-4234, United States of America to TAKEDA PHARMACEUTICAL COMPANY LIMITED, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan, by virtue of Deed of Assignment, dated 03/05/2021. | ||